Enhanced Tumor Inhibition of MDA-MB-231 Breast Carcinoma by the Anti-Tissue Factor Antibody, CNTO 860, Is Mediated by Antibody Dependent Cellular Cytotoxicity

Quantitative in vivo comparisons of the Fcγ receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody

“…Although in vitro assays have more often shown human IgG1 versions of a particular Ab to be far superior to their human IgG4 versions at triggering Ab-dependent cellular cytotoxicity (ADCC) [12], there are also published in vitro ADCC data in which human IgG4 was about as active as IgG1 [10,13]. Even in vivo studies have shown results ranging from the IgG1 version of an anti-tumor Ab having much greater antitumor activity than the IgG4 version of the same Ab [14], to an IgG4 version of an anti-tumor Ab being nearly as active as the IgG1 version of the same Ab [13], to an IgG4 version of an anti-T cell Ab being just as active at mediating clearance of T cells as an IgG1 version of the same Ab [15]. Evidence suggests that the different results are at least in part a reflection of different FcγRs being involved with the particular activity being measured.…”